Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

By V. Arvaniti, G. D’Amico, G. Fede, P. Manousou, E. Tsochatzis, M. Pleguezuelo, Andrew K. Burroughs. Gastroenterology, 2010

1,152 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/488d0c2d56727ede06e23a204352b7cdd8989844

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. P. Ginés
2. M. Bernardi
3. W. Laleman
4. P. Angeli
5. J. Trebicka
6. G. Garcia‐Tsao
7. Aleksander Krag
8. A. Sanyal

In Hepatology

1. P. Ginés
2. M. Bernardi
3. P. Angeli
4. W. Laleman
5. J. Trebicka
6. Rajeshwar P. Mookerjee
7. G. Garcia‐Tsao
8. Aleksander Krag

In Infectious Diseases

1. J. Vila

Citations in the corpus

• Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. (2014, background): “The clinical expression of bacteria-dependent events during cirrhosis includes both chronic systemic and organ-specific damage and intercurrent acute insults (i.e. acute-on-chronic) [120,121].”
• The Cirrhosis Dysbiosis Ratio defines Changes in the Gut Microbiome Associated with Cirrhosis and its Complications (2013, positive): “These infections are the leading cause of multi-organ failure, acuteon-chronic liver failure (ACLF), and death in cirrhosis [4–6].”
• Acute-on chronic liver failure. (2012, background): “The mortality rate of cirrhotic patients with severe bacterial infection with septic shock is about 60–100% [66–70].”
• Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study (2012, methodology): “The empirical antibiotic regimen used in this series was as follows: (1) intravenous (IV) ceftriaxone for SBP, SE, SB, UTI, and sepsis of unknown origin; (2) IV ceftriaxone plus cloxacillin or amoxicillin/clavulanic acid for cellulitis; (3) IV ceftriaxone and a macrolide or levofloxacin (plus clinda”
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. (2014, background): “In a recent study, the occurrence of infection in a cirrhotic patient was suggested to represent a critical step in the progression of cirrhosis [6].”
• Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014 (2009, neutral): “Further, infections are more frequent in patients with decompensated cirrhosis than in those with compensated cirrhosis or chronic hepatitis [69].”
• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, background): “75 and are associated with a 30% onemonth and 63% 12-month mortality [291].”